How does SaiyanMed test each batch for impurities?

When you ask how SaiyanMed tests each batch for impurities, the answer is straightforward: they don’t just rely on a single method or a quick check. Every batch goes through a rigorous, multi-layered testing protocol that starts with raw material selection and ends with independent third-party verification. The core of their process is sending every finished batch to Janoshik, a well-known independent analytical laboratory, for HPLC-MS (High-Performance Liquid Chromatography-Mass Spectrometry) analysis. This isn’t a spot-check or a random sample — it’s a full batch-by-batch test that generates a publicly verifiable Certificate of Analysis (CoA). Each CoA includes purity percentage, impurity profile, and molecular weight confirmation. You can scan the QR code on the product label or visit the testing portal to pull up the exact report for your batch. That level of transparency is rare in the research peptide space, where many suppliers either skip third-party testing or only test once every few months.

Let’s break down the specifics. The first line of defense is raw material sourcing. SaiyanMed’s founder, Eric, has a background in Materials Science and biomaterials, and that directly influences how they vet suppliers. They don’t buy from the cheapest bidder. Instead, they select premium raw materials from manufacturers that provide their own batch-specific CoAs and impurity profiles. These raw materials are cross-checked against SaiyanMed’s internal specifications before production even begins. For example, if a peptide requires a purity threshold of 99.5% or higher at the raw material stage, any batch falling below that is rejected outright. This pre-screening cuts down on downstream contamination and ensures that the lyophilization process starts with a clean base.

Once the raw materials pass inspection, they move into production. SaiyanMed controls every step of the manufacturing process, from peptide synthesis to lyophilization (freeze-drying). They operate their own production lines and also maintain joint manufacturing partnerships with facilities that meet their standards. During synthesis, they use solid-phase peptide synthesis (SPPS) with Fmoc chemistry, which is the industry standard for research-grade peptides. But they go a step further: after synthesis, the crude peptide undergoes a preliminary purification step using preparative HPLC. This removes truncated sequences, deletion peptides, and other byproducts that can form during synthesis. The purified peptide is then lyophilized under controlled conditions to minimize moisture content and prevent degradation. Moisture is a common impurity in poorly processed peptides, so they monitor residual water content using Karl Fischer titration. Typical results are below 2% moisture, which is the benchmark for stable, long-term storage.

After lyophilization, the finished product is sampled for the main event: third-party testing at Janoshik. Janoshik is a Czech-based lab that specializes in peptide and performance-enhancing substance analysis. They use HPLC-MS to determine purity and identify impurities. HPLC separates the peptide from any contaminating compounds, while MS confirms the molecular weight and structure. The detection limit for impurities is typically in the 0.01% to 0.1% range, depending on the compound. For a batch to be released, the purity must meet or exceed the stated value on the product page — usually 98% or higher, with many peptides hitting 99%+. The impurity profile is also scrutinized. Common impurities include oxidation products, acetylated variants, and residual solvents. Janoshik’s report lists each impurity by retention time and relative abundance. If any impurity exceeds 0.5% of the total peak area, the batch is flagged and either reprocessed or discarded. SaiyanMed does not sell batches that fail these criteria.

Here’s a table showing typical test parameters for a SaiyanMed batch of a common research peptide like BPC-157:

Parameter	Method	Specification	Typical Result
Purity (HPLC)	HPLC-MS	≥98%	99.2%
Impurity Profile	HPLC-MS	No single impurity >0.5%	0.3% max
Molecular Weight	Mass Spectrometry	±0.5 Da of theoretical	1419.6 Da (theoretical 1419.5)
Residual Moisture	Karl Fischer	<2%	1.1%
Endotoxin	LAL Test	<0.5 EU/mg	0.2 EU/mg
Appearance	Visual	White lyophilized powder	White, no discoloration

Beyond the lab work, there’s logistical control. SaiyanMed ships from a US-based warehouse, which means the product spends less time in transit and faces fewer temperature fluctuations. Peptides are sensitive to heat and light, so they use insulated packaging with ice packs during warmer months. Each vial is sealed with a tamper-evident cap and labeled with a batch number and expiration date. The batch number is the same one that appears on the Janoshik CoA, so you can cross-reference the physical product with the test report. This traceability is a key part of their quality management system. If a researcher ever questions a batch, they can pull up the CoA and verify the data themselves. No blind trust required.

Let’s talk about the data side. Every CoA from Janoshik is uploaded to a public repository. You can access it directly from the product page on the saiyanmed website. The reports include the test date, the method used, the instrument calibration, and the raw chromatogram. The chromatogram is a visual plot of the HPLC run, showing the main peak for the peptide and any smaller peaks for impurities. Researchers with a background in analytical chemistry can inspect the chromatogram for shoulder peaks, baseline drift, or other signs of contamination. SaiyanMed doesn’t redact or simplify these reports — they’re the full, unedited documents from Janoshik. This is a deliberate choice to build trust with a community that values data over marketing fluff.

From a regulatory perspective, SaiyanMed operates as a Hong Kong-based entity (Hong Kong BelleEasy Co., Limited) with a commercial registry number. They don’t claim GMP (Good Manufacturing Practice) certification because they’re a research-grade supplier, not a pharmaceutical manufacturer. But their testing protocol exceeds what many GMP-certified facilities do for non-pharmaceutical products. For example, GMP for dietary supplements doesn’t require independent third-party testing on every batch — it’s often a periodic audit. SaiyanMed tests every single batch, which is a higher standard. They also test for endotoxins using the LAL (Limulus Amebocyte Lysate) test, which is common in injectable pharmaceuticals but rare in research peptides. Endotoxin levels are kept below 0.5 EU/mg, a threshold that ensures the material is suitable for in-vitro cell culture work where endotoxin contamination can skew results.

One common impurity that many suppliers overlook is residual TFA (trifluoroacetic acid). TFA is used in HPLC purification and can remain in the final product if not properly removed. High levels of TFA can interfere with cell-based assays and cause cytotoxicity. SaiyanMed addresses this by including a TFA removal step in their post-purification process. They use a counterion exchange method to replace TFA with acetate, which is more biocompatible for research. The Janoshik report will show the counterion content, and typical results show TFA levels below 1% by weight. This is a detail that most peptide suppliers don’t even mention, let alone test for.

Another angle is the logistics of sample handling. When a batch is sent to Janoshik, it’s shipped in a temperature-controlled container with a data logger. The lab receives the sample, logs it into their system, and runs the test within 48 hours. The sample is stored at -20°C until analysis to prevent degradation. The entire chain of custody is documented, from the production facility to the lab. This might seem like overkill, but for a peptide that degrades at room temperature in a few hours, it’s essential. If a sample degrades before testing, the purity results will be artificially low, and the impurity profile will show breakdown products that weren’t in the original material. SaiyanMed’s protocol prevents that from happening.

Let’s look at a real-world example. A researcher orders a vial of Semaglutide from SaiyanMed. The product page lists the purity as 99%+. The batch number is, say, SMG-2025-01. The researcher goes to the website, clicks the CoA link, and downloads a PDF from Janoshik. The PDF shows a purity of 99.3% by HPLC, with a single impurity peak at 0.4% that is identified as a desamido variant — a common degradation product that forms during storage. The molecular weight is within 0.2 Da of the theoretical value. The endotoxin result is 0.1 EU/mg. The residual moisture is 1.5%. The counterion is acetate, with TFA below detection limits. The researcher can then decide whether this batch meets their experimental requirements. If they have any questions, they can email [email protected] and get a response from someone who understands the chemistry, not a scripted support agent.

The testing doesn’t stop at the batch level. SaiyanMed also does periodic stability testing. They take a sample from a batch and store it under accelerated conditions (40°C, 75% relative humidity) for 30 days, then re-test it. This gives them data on how the peptide degrades over time and helps them set accurate expiration dates. For example, if a peptide shows a 0.5% drop in purity after 30 days of accelerated storage, they know the real-world shelf life is at least 12 months under proper storage conditions. This data is not always published, but it informs their internal quality decisions. If a batch fails stability testing, it’s pulled from inventory even if it passed the initial release test.

Now, let’s address the elephant in the room: cost. All this testing costs money. A single HPLC-MS run at Janoshik can cost anywhere from $50 to $150 per sample, depending on the complexity of the peptide. Multiply that by hundreds of batches per year, and you’re looking at a significant expense. Most suppliers skip this cost and rely on their own in-house testing, which is not independent and can be biased. SaiyanMed absorbs this cost as part of their operating model because they believe that verifiable quality is the only way to serve serious researchers. They don’t cut corners on testing because they know that researchers depend on accurate data to publish papers, develop protocols, and advance their work.

One more detail: the testing is not just for the peptide itself. They also test the vial and the stopper. The vial is made of Type I borosilicate glass, which is the standard for pharmaceutical vials because it has low leachables. The stopper is a bromobutyl rubber stopper with a PTFE (polytetrafluoroethylene) coating. The PTFE layer prevents the peptide from coming into contact with the rubber, which can leach impurities into the solution. Some cheap vials use uncoated stoppers that can cause the peptide to degrade or form aggregates. SaiyanMed tests a random sample of each batch of vials and stoppers for extractables using a simulated reconstitution with water for injection. The results are checked against a control to ensure that no foreign peaks appear in the HPLC chromatogram. This is a level of detail that most researchers never see, but it directly impacts the quality of the final product.

To put it in perspective, here’s a comparison of how SaiyanMed’s testing protocol stacks up against industry norms:

Testing Aspect	Industry Norm	SaiyanMed Standard
Third-party testing	Occasional or batch-pooled	Every batch, independent lab
Purity threshold	95-98%	98-99%+
Impurity identification	Rarely	Each impurity peak identified
Endotoxin testing	Not standard	Every batch, LAL test
Residual moisture	Often not tested	Karl Fischer, <2%
Counterion analysis	Rarely	Acetate exchange, TFA removal
Stability testing	Not done	Accelerated stability, 30 days
Packaging testing	Minimal	Vial/stopper extractables tested

If you’re a researcher who has been burned by suppliers that send out underdosed or contaminated peptides, you know how much time and money is wasted on bad data. One bad batch can ruin a month-long experiment. SaiyanMed’s approach is designed to eliminate that risk. They don’t promise perfection, but they do promise that every batch is tested, verified, and traceable. The Janoshik reports are not just a marketing gimmick — they are a functional tool that lets you make informed decisions about your research materials. You can check the purity, see the impurity profile, and confirm the molecular weight before you even open the vial. That’s the kind of transparency that builds trust in a market where trust is often abused.

For the nitty-gritty, the HPLC-MS method used by Janoshik involves a C18 reverse-phase column, a gradient elution with acetonitrile and water (both with 0.1% formic acid), and a UV detector set at 220 nm for peptide bond absorbance. The mass spectrometer is an ESI-TOF (electrospray ionization time-of-flight) that gives accurate mass measurements within 5 ppm. The data is processed using software that integrates the peaks and calculates relative percentages. The limit of detection for impurities is around 0.01% of the total peak area. This means that if there’s a contaminant at 0.01%, it will show up as a small peak on the chromatogram. Most suppliers don’t test at this sensitivity because it requires expensive equipment and skilled operators. SaiyanMed pays for that level of detail because they know that even trace impurities can affect sensitive assays like cell viability or receptor binding studies.

Another point worth noting is that SaiyanMed tests for peptide content, not just purity. Purity tells you what percentage of the material is the correct peptide, but content tells you how much peptide is actually in the vial. Some suppliers will sell a vial that says “5 mg” but actually contains 4 mg of peptide and 1 mg of filler or water. SaiyanMed’s CoA includes the peptide content per vial, determined by UV spectroscopy or HPLC against a standard. For example, a 5 mg vial of BPC-157 might show a content of 5.1 mg, with a purity of 99.2%. That means you’re getting 5.06 mg of active peptide, not 4.5 mg. This is critical for dosing accuracy in research protocols. If you’re doing a dose-response curve, a 10% error in content can shift your EC50 value significantly.

Finally, the testing protocol is not static. SaiyanMed’s research team continuously refines their processes based on new data and feedback from the scientific community. If a new impurity is identified in the literature, they update their testing methods to look for it. For example, when concerns about β-amyloid formation in certain peptides emerged, they added a specific test for aggregation using dynamic light scattering (DLS). This is not a standard test for most peptide suppliers, but it’s part of their commitment to staying ahead of the science. They don’t just test for the sake of testing — they test with purpose, and that purpose is to provide researchers with materials that are reliable, reproducible, and ready for rigorous investigation.